MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Vertex Pharmaceuticals Inc

Suletud

SektorTervishoid

484.44 -0.01

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

480.95

Max

490.82

Põhinäitajad

By Trading Economics

Sissetulek

-132M

913M

Müük

142M

2.9B

P/E

Sektori keskmine

30.42

63.778

Aktsiakasum

3.98

Kasumimarginaal

31.353

Töötajad

6,100

EBITDA

-99M

1.2B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+2.94% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. mai 2025

Turustatistika

By TradingEconomics

Turukapital

6.8B

127B

Eelmine avamishind

484.45

Eelmine sulgemishind

484.44

Uudiste sentiment

By Acuity

35%

65%

113 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. veebr 2025, 22:11 UTC

Tulu

Vertex Pharmaceuticals Posts Higher 4Q Revenue

31. jaan 2025, 00:19 UTC

Suurimad hinnamuutused turgudel

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

19. dets 2024, 12:25 UTC

Suurimad hinnamuutused turgudel

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

4. nov 2024, 21:44 UTC

Tulu

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

1. aug 2024, 20:45 UTC

Tulu

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11. veebr 2025, 21:12 UTC

Tulu

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11. veebr 2025, 14:21 UTC

Tulu

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10. veebr 2025, 21:12 UTC

Tulu

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10. veebr 2025, 21:12 UTC

Tulu

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10. veebr 2025, 21:11 UTC

Tulu

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10. veebr 2025, 21:04 UTC

Tulu

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10. veebr 2025, 21:04 UTC

Tulu

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10. veebr 2025, 21:02 UTC

Tulu

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

10. veebr 2025, 21:01 UTC

Tulu

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

10. veebr 2025, 21:01 UTC

Tulu

Vertex Pharmaceuticals 4Q Net $913M >VRTX

10. veebr 2025, 21:01 UTC

Tulu

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

10. veebr 2025, 21:01 UTC

Tulu

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

31. jaan 2025, 09:59 UTC

Kuumad aktsiad

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

4. nov 2024, 22:21 UTC

Tulu

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

4. nov 2024, 21:25 UTC

Tulu

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

4. nov 2024, 21:03 UTC

Tulu

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

4. nov 2024, 21:01 UTC

Tulu

Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX

4. nov 2024, 21:01 UTC

Tulu

Vertex Pharmaceuticals 3Q Net $1.05B >VRTX

4. nov 2024, 21:01 UTC

Tulu

Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX

26. sept 2024, 14:20 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

1. aug 2024, 20:30 UTC

Tulu

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1. aug 2024, 20:03 UTC

Tulu

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1. aug 2024, 20:02 UTC

Tulu

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1. aug 2024, 20:02 UTC

Tulu

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

Võrdlus sarnastega

Hinnamuutus

Vertex Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

2.94% tõus

12 kuu keskmine prognoos

Keskmine 499.09 USD  2.94%

Kõrge 591 USD

Madal 320 USD

Põhineb 27 Wall Streeti analüütiku instrumendi Vertex Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

27 ratings

16

Osta

10

Hoia

1

Müü

Tehniline skoor

By Trading Central

471.5 / 505Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

113 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.